Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Onco-Innovations Ltd. ( (TSE:ONCO) ) has issued an announcement.
Onco-Innovations Limited has entered into a services agreement with Redwood AI Inc. to advance the development of its Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. This collaboration aims to enhance Onco’s drug development capabilities by utilizing Redwood AI’s AI-driven chemistry tools, which can improve synthesis efficiency, compound design, and expand the pipeline of viable analogs. The partnership is part of Onco’s strategy to progress towards First-in-Human studies, potentially accelerating their timeline towards clinical trials and reinforcing their technical capabilities at a crucial preclinical phase.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company focuses on the prevention and treatment of cancer through pioneering research and innovative solutions, with an exclusive worldwide license to patented technology targeting solid tumors.
Average Trading Volume: 109,300
For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.